Physician profile
Wei Lu
NPI 1497284764
$2,896.03
in general payments reported to CMS, 2019-2025
23 companies · $1,488 in 2025
The $1,488 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $217 · 2024: $1,191 · 2025: $1,488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,812 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,812.03 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $699.16 | 2023-2025 | |
| Saluda Medical Americas, INC. | $485.30 | 2024-2025 | Evoke |
| Phathom Pharmaceuticals, INC. | $316.67 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $197.59 | 2023-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $191.76 | 2024-2025 | Stelara, Tremfya, Simponi |
| Pfizer INC. | $120.71 | 2023-2025 | |
| Capsovision, INC. | $120.14 | 2025 | Capsocam Plus |
| Regeneron Healthcare Solutions, INC. | $116.35 | 2023-2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $104.10 | 2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $95.10 | 2024-2025 | |
| Madrigal Pharmaceuticals | $67.42 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $58.56 | 2024-2025 | Omvoh |
| Gilead Sciences, INC. | $50.43 | 2025 | |
| Aimmune Therapeutics, INC. | $49.46 | 2024-2025 | Zenpep |
| E.R. Squibb & Sons, L.L.C. | $38.78 | 2024 | Zeposia |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.31 | 2025 | Plenvu, Xifaxan |
| Novo Nordisk INC | $25.53 | 2025 | Wegovy |
| Axonics, INC. | $24.25 | 2024 | Axonics |
| Celltrion USA INC. | $24.03 | 2025 | Vegzelma |
| Genzyme Corporation | $20.28 | 2024 | |
| Nestle Healthcare Nutrition INC. | $18.04 | 2023 | |
| Springworks Therapeutics, INC. | $17.43 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $16.63 | 2024 | Simlandi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Lu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.